Clinical Trial Update: Positron Emission Tomography Imaging With [F-18] FLT Compared to [F-18] FDG in Cancer Patients for Treatment Evaluation [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 trial comparing PET imaging tracers F-18 FLT and F-18 FDG for treatment evaluation in head and neck cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• F-18 FDG (fluorodeoxyglucose (FDG))
• F-18 FLT (fluorothymidine (FLT))

Snippet

Sponsor: University of California, Irvine | Conditions: Head and Neck Cancer | Phase 2, Phase 3 | Status: WITHDRAWN